[MOL] Tamoxifen's Clinical Applications: Old and New [00554] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Tamoxifen's Clinical Applications: Old and New

Tamoxifen's Clinical Applications: Old and New
    [10/13/2000; Archives of Family Medicine]

The American Cancer Society estimates that this year more than
180,000 women in the United States will develop breast cancer
and more than 40,000 women will die of the disease. According
to a National Cancer Institute model, 5 years of preventive therapy
with tamoxifen citrate reduced the risk of invasive breast cancer
by 49% (P<.00001) in women at increased risk for breast cancer.
The reduction in risk was greater in women with a history of
lobular carcinoma in situ (LCIS; 56% relative risk reduction)
or atypical hyperplasia (86% relative risk reduction). It should
be noted, however, that no benefit was found in 2 European studies
using notably different risk evaluation models and entry criteria.
Because elevated risks of uterine cancer and thromboembolic disease
have been associated with tamoxifen therapy, appropriate counseling
should be given to any woman considering tamoxifen as a means
of reducing breast cancer risk.

Arch Fam Med. 2000;9:906-912

The full article can be found at:


This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email